Emergence of Streptococcus pneumoniae Serotype 12F after Sequential Introduction of 7- and 13-Valent Vaccines, Israel
Assaf Rokney

, Shalom Ben-Shimol, Zinaida Korenman, Nurith Porat, Zeev Gorodnitzky, Noga Givon-Lavi, Merav Ron, Vered Agmon, Ron Dagan, and Lea Valinsky
Author affiliations: Ministry of Health, Jerusalem, Israel (A. Rokney, Z. Korenman, Z. Gorodnitzky, M. Ron, V. Agmon, L. Valinsky); Soroka University Medical Center, Beer Sheva, Israel (S. Ben-Shimol, N. Porat, N. Givon-Lavi); Ben-Gurion University of the Negev, Beer Sheva (S. Ben-Shimol, N. Porat, N. Givon-Lavi, R. Dagan)
Main Article
Figure 3
Figure 3. Streptococcus pneumoniae serotype 12F incidence (cases/100,000 population) by age group, Israel, July 2009–June 2016.
Main Article
Page created: February 15, 2018
Page updated: February 15, 2018
Page reviewed: February 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.